Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Pharmacyclics Turns To Profit In Q1 - Quick Facts

RELATED NEWS
Trade PCYC now with 

Pharmacyclics Inc. (PCYC: Quote) reported that its first-quarter GAAP net income was $75.6 million, or $1.02 per share, compared to GAAP net loss of $14.5 million, or $0.21 loss per share in the year ago quarter.

The non-GAAP net income for the fiscal quarter was $78.8 million or $1.06 income per share, compared to a non-GAAP net loss of $12.4 million, or $0.18 per share last year.

Revenue for the quarter was $102.7 million, compared to $37,000 last year, an increase of approximately $102.7 million.

Revenue for the latest quarter consisted primarily of $100 million of license and milestone revenue due to the Company's achievement of two clinical milestones in connection with the Company's collaboration and license agreement with Janssen Biotech, Inc.

Analysts polled by Thomson Reuters expected the company to report earnings of $0.75 per share on revenues of $87.64 million for the quarter. Analysts' estimates typically exclude special items.

Click here to receive FREE breaking news email alerts for Pharmacyclics Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
A number of major retailers will be open on Thanksgiving for early Black Friday shopping events. Kohl's department stores will kick off Black Friday sales two hours earlier this year, at 6 p.m. Thanksgiving Day, while Macy's, Bon-Ton and Best Buy will open at the same time. J.C. Penney and Sears... Twitter Inc. has replaced its head of product Daniel Graf just six months after luring him over from Google, according to multiple reports. Graf, previously known for his work leading Google Maps, will retain his vice president of product title and work on Twitter's geolocation features, the Wall... LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that its third quarter loss widened slightly from last year, as higher costs and expenses more than offset a 45% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.